| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 27, 2007
Accepted on April 28, 2008
Department of Medicine, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Medicine and Epidemiology, University of Michigan School of Medicine, Ann Arbor, MI; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA; International Diabetes Center, Minneapolis, MN; Department of Medicine, Division of General Internal Medicine, Durham Veterans Administration Medical Center, Duke University, Durham, NC; Department of Internal Medicine, Charles R. Drew University, Los Angeles, CA
* To whom correspondence should be addressed. E-mail: csaudek{at}jhu.edu.
Objective: Diabetes is under-diagnosed. About one-third of people with diabetes do not know they have it, and the average lag between onset and diagnosis is 7 years. This report reconsiders the criteria for diagnosing diabetes, and recommends screening criteria, in order to make case-finding easier for clinicians and patients.
Participants: One of us (RMB) invited experts in the area of diagnosis, monitoring and management of diabetes to form a panel to review the literature and develop consensus regarding the screening and diagnosis of diabetes with particular reference to the use of hemoglobin A1c (HbA1c). Participants met in open session and by email thereafter. Metrika, Inc. sponsored the meeting.
Evidence: Literature search was performed using standard search engines.
Consensus Process: The panel heard each member's discussion of the issues, reviewing evidence prior to drafting conclusions. Principal conclusions were agreed upon, then specific cut-points were discussed in an iterative consensus process.
Conclusions: The main factors in support of using HbA1c as a screening and diagnostic test include: a) HbA1c does not require patients to be fasting; b) HbA1c reflects longer-term glycemia than does plasma glucose; c) HbA1c laboratory methods are now well standardized and reliable; d) errors caused by non-glycemic factors affecting HbA1c such as hemoglobinopathies are infrequent and can be minimized by confirming the diagnosis of diabetes with a plasma glucose (PG)-specific test. Specific recommendations: 1) Screening standards should be established that prompt further testing and closer follow-up, including fasting PG 
100 mg/dl, random PG 130 mg/dl or HbA1c > 6.0%; 2) HbA1c 6.5 - 6.9%, confirmed by a PG-specific test (FPG or OGTT), should establish the diagnosis of diabetes; 3) HbA1c 7%, confirmed by another HbA1c or a PG-specific test (FPG or OGTT) should establish the diagnosis of diabetes.
The recommendations are offered for consideration of the clinical community and interested associations and societies.
This article has been cited by other articles:
 |
|
 |
|
  E. S. Moghissi, M. T. Korytkowski, M. DiNardo, D. Einhorn, R. Hellman, I. B. Hirsch, S. E. Inzucchi, F. Ismail-Beigi, M. S. Kirkman, and G. E. Umpierrez American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control Diabetes Care, June 1, 2009; 32(6): 1119 - 1131. [Full Text] [PDF]
|
|
|
|
 |
|
 K M Goode, J John, A S Rigby, E S Kilpatrick, S L Atkin, T Bragadeesh, A L Clark, and J G F Cleland Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus Heart, June 1, 2009; 95(11): 917 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Selvin, H. Zhu, and F. L. Brancati Elevated A1C in Adults Without a History of Diabetes in the U.S. Diabetes Care, May 1, 2009; 32(5): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Preiss, S. Zetterstrand, J. J.V. McMurray, J. Ostergren, E. L. Michelson, C. B. Granger, S. Yusuf, K. Swedberg, M. A. Pfeffer, H. C. Gerstein, et al. Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program Diabetes Care, May 1, 2009; 32(5): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Matrozova, O. Steichen, L. Amar, S. Zacharieva, X. Jeunemaitre, and P.-F. Plouin Fasting Plasma Glucose and Serum Lipids in Patients With Primary Aldosteronism: A Controlled Cross-Sectional Study Hypertension, April 1, 2009; 53(4): 605 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, K. Park, F. Comer, L. C. Hsieh-Wilson, C. D. Saudek, and G. W. Hart Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Diabetes, February 1, 2009; 58(2): 309 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sheehy, D. B. Coursin, and R. A. Gabbay Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus Mayo Clin. Proc., January 1, 2009; 84(1): 38 - 42. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three Diabetes Care, December 1, 2008; 31(12): 2404 - 2409. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden American College of Endocrinology Pre-Diabetes Consensus Conference: Part One Diabetes Care, October 1, 2008; 31(10): 2062 - 2069. [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Aroda and R. Ratner Approach to the Patient with Prediabetes J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3259 - 3265. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
